前列腺癌30次分割、72 Gy放疗方案的长期疗效

Long-term Outcomes of Radiotherapy Regimen of 72 Gy in 30 Fractions for Prostate Cancer.

作者信息

Tamari Keisuke, Oh Ryoong-Jin, Masai Norihisa, Shiomi Hiroya, Otani Keisuke, Suzuki Osamu, Ogawa Kazuhiko

机构信息

Miyakojima iGRT Clinic, Osaka, Japan

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.

出版信息

Anticancer Res. 2018 Jul;38(7):4207-4212. doi: 10.21873/anticanres.12716.

DOI:10.21873/anticanres.12716

PMID:29970552

Abstract

BACKGROUND/AIM: The long-term efficacy and safety of moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) in prostate cancer remains uncertain. This study aimed to evaluate MH-IMRT regimen of 72 Gy in 30 fractions in patients with prostate cancer.

PATIENTS AND METHODS

The outcomes of 412 consecutive prostate cancer patients, who received MH-IMRT between May 2007 and December 2012, were retrospectively reviewed. The median patient age was 70.9 (range=50-84) years. Late gastrointestinal (GI) and genitourinary (GU) toxicity rates were evaluated according to the CTCAE ver. 3.0. The overall survival, biochemical relapse-free survival rate (bRFS), late GI toxicity, and GU toxicity rates were analyzed with the Kaplan-Meier method.

RESULTS

The median follow-up was 71.5 (range, 1.4-124.8) months. The 5-year bRFS rate was 93.2%. The 5-year grade ≥2 late GI and GU toxicity rates were 3.3% and 4.5%, respectively.

CONCLUSION

MH-IMRT regimen of 72 Gy in 30 fractions was effective and safe for prostate cancer patients.

摘要

背景/目的：中度分割调强放射治疗（MH-IMRT）用于前列腺癌的长期疗效和安全性仍不确定。本研究旨在评估前列腺癌患者接受30次分割、总剂量72 Gy的MH-IMRT方案的效果。

患者与方法

回顾性分析2007年5月至2012年12月期间连续接受MH-IMRT的412例前列腺癌患者的治疗结果。患者年龄中位数为70.9岁（范围50 - 84岁）。根据美国国立癌症研究所不良事件通用术语标准第3.0版评估晚期胃肠道（GI）和泌尿生殖系统（GU）毒性发生率。采用Kaplan-Meier法分析总生存率、生化无复发生存率（bRFS）、晚期GI毒性和GU毒性发生率。